Tissue microarray sampling strategy for prostate cancer biomarker analysis.
about
Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomyADAM15 disintegrin is associated with aggressive prostate and breast cancer diseaseThe tissue microarray data exchange specification: implementation by the Cooperative Prostate Cancer Tissue ResourceInternet-based Profiler system as integrative framework to support translational research.Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort.Living Cell Microarrays: An Overview of ConceptsDNA topoisomerase IIα and mitosin expression predict meningioma recurrence better than histopathological grade and MIB-1 after initial surgery.Phenotypic composition of salivary gland tumors: an application of principal [corrected] component analysis to tissue microarray data.A novel method for preparation of tissue microarrayRHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease.Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers.Breast cancer diagnosis using a microfluidic multiplexed immunohistochemistry platform.Assessment of automated image analysis of breast cancer tissue microarrays for epidemiologic studies.Extending the tissue microarray data exchange specification for inclusion of data analysis results.Tissue microarrays: one size does not fit allThe effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy.Matrix metalloproteinases and angiogenic factors: predictors of survival after radical prostatectomy for clinically organ-confined prostate cancer?Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissuesBiomarkers in drug discovery and development: from target identification through drug marketing.Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer.Construction of tissue microarrays from core needle biopsies - a systematic literature review.Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markersRelevance of nuclear and cytoplasmic von hippel lindau protein expression for renal carcinoma progression.Tissue microarrays in urology.Tissue microarrays: applications in genomic research.Assessment of the American Joint Committee on Cancer staging (sixth and seventh editions) for clinically localized prostate cancer treated with external beam radiotherapy and comparison with the National Comprehensive Cancer Network risk-stratificatTechnology insight: Identification of biomarkers with tissue microarray technology.The tissue micro-array as a translational research tool for biomarker profiling and validation.Biomarker discovery using protein microarray technology platforms: antibody-antigen complex profiling.Construction of tissue microarrays from prostate needle biopsy specimens.Identification of common tumor signatures based on gene set enrichment analysis.Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness.Advances in cancer tissue microarray technology: Towards improved understanding and diagnostics.Sampling strategies for tissue microarrays to evaluate biomarkers in ovarian cancer.Aberrant cytoplasmic expression of p63 and prostate cancer mortality.Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer.Preoperative radiochemotherapy is successful also in patients with locally advanced rectal cancer who have intrinsically high apoptotic tumours.Multiplexed fluorescence imaging of tumor biomarkers in gene expression and protein levels for personalized and predictive medicine.Expression and clinical value of EGFR in human meningiomas.Pathology in prostate research: optimizing tissue quality.
P2860
Q24652928-56ADCD5F-5680-4BF7-9C88-D10D7350B412Q24676359-147082E1-D52B-4D86-844C-7A8BF191287DQ24801209-05C6D34E-A152-4E76-89D8-F232371804C0Q25257221-B8EECBE4-BFAC-46ED-BE75-C1C4F385AE1AQ27852034-EC13986A-7311-48E3-87A5-443F81E53010Q28073823-F8BC79C1-C0C3-459A-B5EA-90115F2D03B2Q30359384-A6A249F7-7CD8-4B39-9B39-C90287410324Q30923772-1EA514EE-430E-41AB-B615-B33B866670C0Q33198298-CB844D29-E67A-474E-AE74-934D74473A2BQ33499385-88D83026-C3EE-400E-B507-CEF74E982A54Q33561179-24BAE4F5-52F2-46F5-9FA4-BC68BA42BA2DQ33573511-7364EA20-88AA-4AAF-AB46-ACA06FDE1B0BQ33781177-F3CF34A9-3655-44A0-8E15-E68F013396A8Q33900060-FA05645E-FA51-4477-BB64-2CF789CC1A24Q34020050-2D2023CA-2636-4D90-99B4-15431DB81893Q34187693-1C153C33-D6C4-438C-8582-DA2672842E43Q34254356-BA673F40-0138-40AD-919F-0CF364BB9028Q35023423-83DA2824-93F0-46EB-B8C7-A6FFA126CC87Q35118033-D1F7EFAB-E711-4A7F-9BB8-DFA082C21162Q35554809-C4350D1F-4C15-44BE-B799-5424F511F5A6Q35743491-9271F591-8BBC-4826-B9AE-7634F32E0DECQ35754783-818F5342-85EA-4970-94AB-F46265831B90Q35792041-F4BF8221-3264-4D87-933E-F1CA37A54E96Q35817170-6AD739A9-2EE3-464A-BF21-D0612BD341B8Q36099365-08B0C6B9-A806-4ECB-BE74-CE28F595F5C6Q36133745-BB5C5F0B-B4BE-4229-AAD8-B87DB94AF54CQ36303882-7B75FBFC-DCF7-4546-9E79-7DCA95DF8750Q36318018-1C5E5AEA-057E-446D-9F79-B783FA36F102Q36322149-F132A36E-C479-4A40-8234-098BCD000332Q36615192-CC855970-4E46-4361-A8AF-67E008EF1A16Q36630265-97D76BAB-82C0-4EA5-800D-1F712B790FA6Q36943119-63349508-7F4F-4DC5-94F6-3ADF1182F3EDQ36973076-55F2AE2C-449A-4A53-8FE6-C2113B55B0CCQ37147224-E76C2005-8893-446D-950E-FB300219D661Q37216001-69C3F695-AFE7-4164-BC34-16E0B9A3FC1FQ37220650-E707B2FB-4A56-4611-9F8B-616FB8889FD3Q37321935-9CFF1A4C-2A4B-40C4-9849-F69BCF760925Q37595545-8A2E4B8A-BB97-4B85-94E2-30F560815A45Q37732068-DB90BAC2-825C-4FB2-82EE-305AE84818E3Q37878467-BD2FE843-B56F-48F1-9482-8CF237213978
P2860
Tissue microarray sampling strategy for prostate cancer biomarker analysis.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Tissue microarray sampling strategy for prostate cancer biomarker analysis.
@en
Tissue microarray sampling strategy for prostate cancer biomarker analysis.
@nl
type
label
Tissue microarray sampling strategy for prostate cancer biomarker analysis.
@en
Tissue microarray sampling strategy for prostate cancer biomarker analysis.
@nl
prefLabel
Tissue microarray sampling strategy for prostate cancer biomarker analysis.
@en
Tissue microarray sampling strategy for prostate cancer biomarker analysis.
@nl
P1476
Tissue microarray sampling strategy for prostate cancer biomarker analysis.
@en
P2093
Myla Strawderman
Rodney Dunn
P304
P356
10.1097/00000478-200203000-00004
P407
P577
2002-03-01T00:00:00Z